packageBrentuximabVedotin

brentuximab vedotin

Extends from Pharmacolibrary.Interfaces.PartialSubstance (Identity and physicochemical constants of one drug (Drugs.Substances)).

Information

Brentuximab vedotin is an antibody-drug conjugate used to treat lymphoma, including Hodgkin lymphoma and several types of T-cell and non-Hodgkin lymphoma. It is approved and authorised in the European Union, and is also being investigated for additional uses.

Summary written by glm-5.3-flash from Wikidata Q422324 and the WHO ATC classification and the EMA medicines list; not checked by a person.

name:brentuximab vedotin
ATC codes:L01FX05
DrugBank:DB08870
Wikidata:Q422324
molar mass:150500 g/mol (Drugs.Common 25.09, not verified)

Metabolites

DM1DM1molar mass unknown
MMAEMMAE718 g/mol (paper)
MonomethylAuristatinEMMAEmonomethyl auristatin E (MMAE)molar mass unknown

Parameters

TypeNameDefaultDescription
Stringname (from PartialSubstance)""INN / common name
String[:]atcCodes (from PartialSubstance)fill("", 0)all WHO ATC codes of the drug
StringdrugbankId (from PartialSubstance)""e.g. DB00758
StringpubchemCid (from PartialSubstance)""PubChem compound id
StringchebiId (from PartialSubstance)""ChEBI id (number)
StringwikidataId (from PartialSubstance)""e.g. Q410238
Stringformula (from PartialSubstance)""molecular formula
Modelica.Units.SI.MolarMassM (from PartialSubstance)0molar mass; 0 = unknown
ReallogP (from PartialSubstance)Modelica.Constants.infoctanol-water partition coefficient (log10); inf = unknown

Contents

NameDescription
DM1metabolite: DM1
MMAEmetabolite: MMAE
MonomethylAuristatinEMMAEmetabolite: monomethyl auristatin E (MMAE)